AGN:NYE-Allergan plc (USD)

COMMON STOCK | Other | NYE

Last Closing Price

USD 177.10

Change

+0.79 (+0.45)%

Market Cap

USD 57.75B

Volume

4.58M

Average Target Price

USD 201.00 (+13.50%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BMS Bemis Company, Inc

N/A

USD370,676,430.93B 1,000,000.00 N/A
NAO Nordic American Offshore Ltd

N/A

USD387,070.41B N/A N/A
ITC ITC Holdings Corp

-12,550.00 (-100.00%)

USD3,166.52B 22.84 N/A
USB-PA U.S. Bancorp PERP PFD SER A

N/A

USD1,217.49B 206.60 N/A
MSF Morgan Stanley Emerging Market..

N/A

USD1,000.65B 24.60 N/A
HSBC-PA HSBC Holdings plc ADR A 1/40PF..

-0.11 (-0.44%)

USD509.03B 52.71 N/A
SAN-PB Banco Santander, S.A. GTD PFD ..

+0.55 (+2.70%)

USD323.14B 46.18 N/A
BAC-PW Bank of America Corporation

N/A

USD267.69B 9.46 N/A
BAC-PY Bank of America Corporation

N/A

USD263.53B 9.36 N/A
BEL Belmond Ltd

N/A

USD261.58B 15.94 N/A

ETFs Containing AGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 6.22 % 0.35 %

-0.68 (-0.53%)

USD0.34B
XPH SPDR S&P Pharmaceuticals .. 4.73 % 0.35 %

-0.13 (-0.36%)

USD0.19B
IHE iShares U.S. Pharmaceutic.. 4.71 % 0.42 %

-1.06 (-0.78%)

USD0.32B
CACG ClearBridge All Cap Growt.. 2.24 % 0.54 %

-0.22 (-0.75%)

USD0.15B
GURU Global X Guru Index ETF 2.03 % 0.75 %

-0.38 (-1.38%)

USD0.05B
PVAL Principal Contrarian Valu.. 0.00 % 0.29 %

N/A

USD4.96M
PBI Pitney Bowes Inc 0.00 % 0.00 %

-0.19 (-8.52%)

USD0.40B
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.10 (-1.00%)

USD8.05M

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.36% 68% D+ 83% B
Dividend Return 0.39% 19% F 19% F
Total Return -6.97% 69% D+ 83% B
Trailing 12 Months  
Capital Gain 19.95% 86% B 95% A
Dividend Return 2.00% 58% F 49% F
Total Return 21.95% 86% B 95% A
Trailing 5 Years  
Capital Gain -40.26% 36% F 32% F
Dividend Return 3.16% 17% F 12% F
Total Return -37.09% 35% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -12.01% 9% F 8% F
Dividend Return 1.05% 9% F 22% F
Total Return -10.96% 9% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 17.86% 55% F 53% F
Risk Adjusted Return -61.36% 9% F 4% F
Market Capitalization 57.75B 97% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.00 34% F 26% F
Price/Book Ratio 0.99 53% F 51% F
Price / Cash Flow Ratio 7.98 30% F 39% F
EV/EBITDA 9.75 35% F 43% F
Management Effectiveness  
Return on Equity -8.54% 11% F 16% F
Return on Invested Capital 1.50% 21% F 20% F
Return on Assets 0.90% 16% F 23% F
Debt to Equity Ratio 31.14% 80% B- 76% C
Technical Ratios  
Short Ratio 3.88 36% F 22% F
Short Percent 4.57% 43% F 59% F
Beta 1.49 17% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector